Subscribe To
CLLS / Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript
CLLS News
By Seeking Alpha
November 3, 2023
Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin more_horizontal
By GlobeNewsWire
November 1, 2023
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology compa more_horizontal
By GlobeNewsWire
September 27, 2023
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com more_horizontal
By Seeking Alpha
August 4, 2023
Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript
Cellectis SA (NASDAQ:CLLS ) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andr more_horizontal
By Pulse2
February 5, 2023
CLLS Stock: 23.01% Drop Explaination
The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why. more_horizontal
By GlobeNewsWire
December 1, 2022
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology co more_horizontal
By GlobeNewsWire
September 1, 2022
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology c more_horizontal
By The Motley Fool
May 20, 2022
Why Cellectis' Shares Rose 22.7% This Week
The company bucked the recent downward trend for biotech companies. more_horizontal